Rallybio Corp teeters on a high-stakes tightrope: Biotechnology promise amid financial and clinical uncertainty.
Overview
Rallybio Corp, led by seasoned rare-disease experts, focuses on developing treatments for severe and rare conditions with no approved products but promising early-stage drug candidates like RLYB116 for complement system disorders. In association with strategic collaborators like Johnson & Johnson, the company targets high-value, unmet rare disease areas, aiming to transform into a revenue-generating entity. However, this high-risk, high-reward early biotech lacks proof of concept with substantial scientific and market hurdles ahead.